Saeed Ahmed Memon: Can Hydralazine Stop Aggressive Brain Cancer Cells?
Saeed Ahmed Memon, Psychiatrist at Health Department Govt of SINDH Pakistan, shared a post on LinkedIn:
“Medical researchers at the University of Pennsylvania have recently unlocked the precise molecular secrets of Hydralazine, a cardiovascular medication that has been utilized globally for decades.
Scientists discovered that this established drug fundamentally works by blocking a specific oxygen-sensing enzyme known as ADO, which typically signals blood vessels to severely constrict when oxygen levels drop.
By actively shutting down this specific enzyme, the medication stabilizes cellular proteins and forces blood vessels to relax.
However, while mapping this exact cardiovascular mechanism, researchers stumbled upon an incredible secondary application regarding one of the most notoriously aggressive forms of brain cancer.
The exact oxygen-sensing pathway that constricts blood vessels is identically utilized by Glioblastoma tumors to survive and thrive in low-oxygen environments.
When scientists applied Hydralazine to these malignant cells, the medication did not kill them directly, but instead trapped the cancer in a dormant, non-dividing state known as senescence, abruptly halting the tumor’s growth.
This remarkable scientific breakthrough highlights the massive, untapped potential of repurposing established, safety-tested pharmaceutical compounds to combat highly complex oncological challenges.”
Stay updated with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering